drugset

drugset / Trial / NCT04252859

[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma

NCT04252859 ↗

Phase 2 Terminated 44 enrolled University of Utah

Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

FES PET/CT imaging for invasive lobular cancer

Timeline

Start: 2020-12-11
Primary completion: 2024-12-07
Completion: 2024-12-07

Publications

Covington MF, Hoffman JM, Morton KA, Buckway B, Boucher KM, Rosenthal RE, Porretta JM, Brownson KE, Matsen CB, Vaklavas C, Ward JH, Wei M, Buys SS, Chittoria N, Yakish ED, Archibald ZG, Burrell LD, Butterfield RI, Yap JT. Prospective Pilot Study of 18F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas. AJR Am J Roentgenol. 2023 Aug;221(2):228-239. doi: 10.2214/AJR.22.28809. Epub 2023 Mar 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	F-18 16 Alpha-Fluoroestradiol	Diagnostic / imaging agent	222 mbq	—

Indications